Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02805283 · ClinicalTrials.gov registry record
Dapagliflozin Patient Satisfaction Survey
A clinical trial of Diabetes Mellitus, Type 2, sponsored by AstraZeneca.
- Completed
- Registry status
- 653
- Enrollment target
- 1
- Study location
NCT02805283 is a study of Diabetes Mellitus, Type 2 that has completed, run by AstraZeneca. The registered enrollment target is 653 participants, below the 4,483-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02805283, a study of Diabetes Mellitus, Type 2, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 653 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the diabetes related treatment satisfaction for patients with type 2 diabetes mellitus
Conditions Studied
Study Locations (1)
Minnesota
- Reasearch Site - Eden Prairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 653 participants |
| Start Date | 2016-06-22 |
| Est. Completion | 2018-10-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02805283
The ClinicalTrials.gov registry entry for NCT02805283 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 653 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,483-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (85% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 0 interventions.
NCT02805283 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02805283 about?
NCT02805283 is a clinical study titled "Dapagliflozin Patient Satisfaction Survey". The purpose of this study is to evaluate the diabetes related treatment satisfaction for patients with type 2 diabetes mellitus
What is the current status of trial NCT02805283?
This trial is currently completed. The enrollment target is 653 participants. The study started on 2016-06-22. Estimated completion is 2018-10-29.
What conditions does trial NCT02805283 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
Who is sponsoring clinical trial NCT02805283?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02805283 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.